Download PDF
Semin Thromb Hemost 2022; 48(04): 459-464
DOI: 10.1055/s-0041-1733924
Review Article

Safety and Efficacy of Rivaroxaban for Inferior Vena Cava Thrombosis after Successful Catheter-Directed Thrombolysis

Jun Du
1   Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
,
Menglin Nie
2   Department of Vascular Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
,
Zhitong Yan
2   Department of Vascular Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
,
Jian Fu
2   Department of Vascular Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
,
Jianming Sun
2   Department of Vascular Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
,
Fanyun Liu
2   Department of Vascular Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Rivaroxaban use for inferior vena cava (IVC) thrombosis after successful catheter-directed thrombolysis (CDT) is rarely reported. This study aimed at investigating the safety and efficacy of rivaroxaban for IVC thrombosis after CDT. The clinical data on 38 consecutive patients with IVC thrombosis (68% male; mean age, 51.5 ± 16.5), who received rivaroxaban after CDT between July 2017 and January 2020, were retrospectively analyzed in this study. Safety and efficacy of rivaroxaban (bleedings and recurrent venous thromboembolism), cumulative prevalence of post-thrombotic syndrome (PTS), primary patency, clinically driven target lesion revascularization rate, and other adverse events including all-cause mortality and vascular events (systemic embolism, acute coronary syndrome, ischemic stroke, and transient ischemic attack) were retrospectively analyzed. Of the 38 patients who received rivaroxaban for IVC thrombosis after CDT, 27 (71%) had an anticoagulant duration of 6 months and 11 patients (29%) of more than 6 months. Four patients (10%) suffered recurrent thrombosis. No patient suffered major bleeding, while clinically relevant nonmajor bleeding occurred in two (5%) patients. The cumulative prevalence of PTS was 18% (7/38) during the 12 months follow-up period. Primary patency at 1, 3, 6, and 12 months was 97, 92, 90, and 90%, respectively. According to follow-up data, the clinically driven target lesion revascularization of this study was 10%. Cardiovascular events and mortality did not occur in any patient during the study period. Rivaroxaban for IVC thrombosis after successful CDT can be safe and effective.

Keywords

rivaroxaban - inferior vena cava - thrombosis - catheter-directed thrombolysis - anticoagulation


Publication History

Article published online:
08 October 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Alkhouli M, Zack CJ, Zhao H, Shafi I, Bashir R. Comparative outcomes of catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of inferior vena caval thrombosis. Circ Cardiovasc Interv 2015; 8 (02) e001882
    CrossrefPubMedGoogle Scholar
  • 2 Bartholomew JR. Update on the management of venous thromboembolism. Cleve Clin J Med 2017; 84 (12, Suppl 3): 39-46
    CrossrefPubMedGoogle Scholar
  • 3 Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12 (08) 464-474
    CrossrefPubMedGoogle Scholar
  • 4 Agnelli G, Verso M, Ageno W. et al; MASTER investigators. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res 2008; 121 (05) 605-610
    CrossrefPubMedGoogle Scholar
  • 5 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (23, Suppl 1): I4-I8
    CrossrefPubMedGoogle Scholar
  • 6 Kahn SR. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis 2006; 21 (01) 41-48
    CrossrefPubMedGoogle Scholar
  • 7 Stein PD, Matta F, Yaekoub AY. Incidence of vena cava thrombosis in the United States. Am J Cardiol 2008; 102 (07) 927-929
    CrossrefPubMedGoogle Scholar
  • 8 Alkhouli M, Morad M, Narins CR, Raza F, Bashir R. Inferior Vena Cava Thrombosis. JACC Cardiovasc Interv 2016; 9 (07) 629-643
    CrossrefPubMedGoogle Scholar
  • 9 McAree BJ, O'Donnell ME, Fitzmaurice GJ, Reid JA, Spence RA, Lee B. Inferior vena cava thrombosis: a review of current practice. Vasc Med 2013; 18 (01) 32-43
    CrossrefPubMedGoogle Scholar
  • 10 Konstantinides SV, Torbicki A, Agnelli G. et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35 (43) 3033-3069 , 3069a–3069k
    CrossrefPubMedGoogle Scholar
  • 11 Nakamura M, Yamada N, Ito M. Novel anticoagulant therapy of venous thromboembolism: current status and future directions. Ann Vasc Dis 2017; 10 (02) 92-98
    CrossrefPubMedGoogle Scholar
  • 12 Beyer-Westendorf J, Ageno W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost 2015; 113 (02) 231-246
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016; 41 (01) 206-232
    CrossrefPubMedGoogle Scholar
  • 14 Bauersachs R, Berkowitz SD, Brenner B. et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 15 Prins MH, Lensing AW, Bauersachs R. et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11 (01) 21
    CrossrefPubMedGoogle Scholar
  • 16 Ageno W, Mantovani LG, Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016; 3 (01) e12-e21
    CrossrefPubMedGoogle Scholar
  • 17 Sakatani A, Nishio M, Kume K, Doi Y, Hirooka K. Rivaroxaban for fully occlusive inferior vena cava filter thrombus. Circ J 2019; 83 (07) 1616
    CrossrefPubMedGoogle Scholar
  • 18 Enden T, Haig Y, Kløw NE. et al; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379 (9810): 31-38
    Google Scholar
  • 19 Kakkos SK, Gohel M, Baekgaard N. et al; Esvs Guidelines Committee. Editor's choice—European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 2021; 61 (01) 9-82
    CrossrefPubMedGoogle Scholar
  • 20 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 21 Nagarsheth KH, Sticco C, Aparajita R. et al. Catheter-directed therapy is safe and effective for the management of acute inferior vena cava thrombosis. Ann Vasc Surg 2015; 29 (07) 1373-1379
    CrossrefPubMedGoogle Scholar
  • 22 Nie M, Wang H, Fu J, Liu F, Chen Y, Sun J. Outcomes of Aspirex®S thrombectomy system combined with catheter-directed thrombolysis for treating bilateral lower extremity deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 2021; 9 (05) 1112-1118
    CrossrefPubMedGoogle Scholar
  • 23 Kang JM, Park KH, Ahn S. et al. Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Sci Rep 2019; 9 (01) 20356
    CrossrefPubMedGoogle Scholar
  • 24 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 25 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
    CrossrefPubMedGoogle Scholar
  • 26 Laird JR, Schneider PA, Tepe G. et al; IN.PACT SFA Trial Investigators. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol 2015; 66 (21) 2329-2338
    CrossrefPubMedGoogle Scholar
  • 27 Kido K, Noyes E, Gutnik L. Successful use of rivaroxaban in inferior vena cava thrombosis provoked by multiple traumatic injuries and surgeries: a case report. J Clin Pharm Ther 2017; 42 (05) 631-633
    CrossrefPubMedGoogle Scholar
  • 28 Alkhouli M, Bashir R. Inferior vena cava filters in the United States: less is more. Int J Cardiol 2014; 177 (03) 742-743
    CrossrefPubMedGoogle Scholar
  • 29 Ye K, Qin J, Yin M, Liu X, Lu X. Outcomes of pharmacomechanical catheter-directed thrombolysis for acute and subacute inferior vena cava thrombosis: a retrospective evaluation in a single institution. Eur J Vasc Endovasc Surg 2017; 54 (04) 504-512
    CrossrefPubMedGoogle Scholar
  • 30 Imberti D, Dentali F, Ageno W. et al. Evidence and clinical judgment: vena cava filters. Thromb Haemost 2014; 111 (04) 618-624
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Kahn SR, Shbaklo H, Lamping DL. et al. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost 2008; 6 (07) 1105-1112
    CrossrefPubMedGoogle Scholar
  • 32 Kucher N, Aujesky D, Beer JH. et al. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER). Thromb Haemost 2016; 116 (03) 472-479
    PubMedGoogle Scholar
  • 33 Arabi M, Krishnamurthy V, Cwikiel W. et al. Endovascular treatment of thrombosed inferior vena cava filters: techniques and short-term outcomes. Indian J Radiol Imaging 2015; 25 (03) 233-238
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Zhang X, Huang J, Peng Z. et al. Comparing safety and efficacy of rivaroxaban with warfarin for patients after successful stent placement for chronic iliofemoral occlusion: a retrospective single institution study. Eur J Vasc Endovasc Surg 2021; 61 (03) 484-489
    CrossrefPubMedGoogle Scholar
  • 35 Sebastian T, Hakki LO, Spirk D. et al. Rivaroxaban or vitamin-K antagonists following early endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis. Thromb Res 2018; 172: 86-93
    CrossrefPubMedGoogle Scholar